Key result
Self-expanding valves show no difference in 30-day device success versus balloon-expandable valves in bicuspid TAVR.
Why the study?
Does self-expanding transcatheter aortic valve implantation improve early/30-day device success compared to balloon-expandable transcatheter aortic valve implantation in patients with bicuspid aortic valve stenosis?
Meta-Analysis (n=534)
Does self-expanding transcatheter aortic valve implantation improve early/30-day device success compared to balloon-expandable transcatheter aortic valve implantation in patients with bicuspid aortic valve stenosis?
Answers are grounded in this paper and cite their sources.
This systematic review and meta-analysis found no clear difference in 30-day device success between balloon-expandable and self-expanding transcatheter heart valves in patients with bicuspid aortic valve stenosis, though current head-to-head evidence remains sparse and observational.
The comparative performance of balloon-expandable (BEV) and self-expanding (SEV) transcatheter heart valves in bicuspid aortic valve (BAV) stenosis remains uncertain. We systematically reviewed contemporary BAV-TAVR literature published from 2015 to 2025. The broader qualitative evidence map comprised 69 reports, including device-specific and comparative cohorts; however, only studies with extractable arm-level BEV-versus-SEV data were eligible for quantitative comparative pooling. Three head-to-head cohorts contributed to early/30-day device success (BEV 302/353; SEV 160/181). The pooled RR for SEV versus BEV was 1.03 (95% CI 0.96-1.09; I2=0%). Two cohorts contributed to 30-day permanent pacemaker implantation (PPI), showing a numerically higher but non-significant risk with SEV (RR 2.01; 95% CI 0.93-4.37; I2=0%). Only one study provided compatible 30-day arm-level data for moderate-or-greater paravalvular leak (PVL), precluding pooling. Adjusted and single-arm observational evidence suggested possible platform-specific differences in hemodynamics, PVL and conduction outcomes, but these data were not interpreted as evidence of comparative equivalence or superiority. Available head-to-head evidence does not demonstrate a clear difference in early device success between contemporary BEV and SEV in BAV, but the evidence is sparse, predominantly observational and imprecise. The findings should not be interpreted as proof of equivalence. Prospective comparative studies with standardized BAV phenotyping are required.
No takes yet. Share an insight, caveat, or question.
Chidambaram et al. (2026) conducted a meta-analysis in Bicuspid aortic valve stenosis undergoing transcatheter aortic valve replacement (n=534). Self-expanding transcatheter heart valves (SEV) vs. Balloon-expandable transcatheter heart valves (BEV) was evaluated on Early/30-day device success (RR 1.03, 95% CI 0.96-1.09). Self-expanding valves showed no clear difference in 30-day device success versus balloon-expandable valves in bicuspid aortic valve TAVR.
Synapse has enriched 10 related papers. Consider them for comparative context: